We are live on ! Find out more
ASBP

Aspire Biopharma
ASBP

14 hedge funds and large institutions have $17M invested in Aspire Biopharma in 2023 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 51 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.07% less ownership

Funds ownership: 0.07% → 0% (-0.07%)

75% less funds holding

Funds holding: 57 → 14 (-43)

80% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 5

84% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 51

94% less capital invested

Capital invested by funds: $268M → $17M (-$251M)

Holders
14
Holders Change
-43
Holders Change %
-75.44%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
1
Reduced
5
Closed
51
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AI
Arena Investors
New York
+$1.57M
2
ETH
Exos TFP Holdings
New York
+$1.57M
3
PSAMP
P. Schoenfeld Asset Management (PSAM)
New York
+$1.57M
4
SIM
Sandia Investment Management
Massachusetts
+$1.57M
5
CM
Cohanzick Management
New York
+$741K

Top Sellers

Rank Fund Capital Flow
1
GCL
Glazer Capital LLC
New York
-$23.3M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$22.1M
3
SCM
Saba Capital Management
New York
-$21M
4
FTCM
First Trust Capital Management
Illinois
-$13.2M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$12.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
26
Millennium Management
New York
– -$5.78M -458 Closed
MF
27
Magnetar Financial
Illinois
– -$5.28M -420 Closed
WAM
28
Wolverine Asset Management
Illinois
– -$5.26M -419 Closed
CF
29
Cantor Fitzgerald
New York
– -$5.25M -417 Closed
Goldman Sachs
30
Goldman Sachs
New York
– -$4.75M -377 Closed
Balyasny Asset Management
31
Balyasny Asset Management
Illinois
– -$4.21M -335 Closed
Verition Fund Management
32
Verition Fund Management
Connecticut
– -$4.19M -333 Closed
MC
33
Meteora Capital
Florida
– -$4.06M -322 Closed
CCA
34
Castle Creek Arbitrage
Colorado
– -$3.36M -267 Closed
SRCM
35
Sage Rock Capital Management
New York
– -$3.25M -258 Closed
Nomura Holdings
36
Nomura Holdings
Japan
– -$3.15M -250 Closed
SCM
37
Shaolin Capital Management
Florida
– -$3.15M -250 Closed
CC
38
Centiva Capital
New York
– -$2.64M -210 Closed
CIM
39
Cowen Investment Management
New York
– -$2.63M -208 Closed
WA
40
Whitebox Advisors
Minnesota
– -$2.63M -208 Closed
UOC
41
UBS O'Connor
Illinois
– -$2.38M -190 Closed
BFM
42
Boothbay Fund Management
New York
– -$2.2M -175 Closed
WP
43
Woodline Partners
California
– -$2.1M -167 Closed
PAMP
44
Polar Asset Management Partners
Ontario, Canada
– -$1.84M -146 Closed
Marshall Wace
45
Marshall Wace
United Kingdom
– -$1.61M -128 Closed
CCM
46
CAAS Capital Management
New York
– -$1.57M -125 Closed
PMAM
47
Picton Mahoney Asset Management
Ontario, Canada
– -$1.57M -125 Closed
SFM
48
Spartan Fund Management
Canada
– -$1.23M -98 Closed
WRBC
49
W.R. Berkley Corp
Connecticut
– -$1.12M -89 Closed
BI
50
Bulldog Investors
New Jersey
– -$1.08M -86 Closed
1
2
3

ASBP Hedge Fund Activity: Q2 2023 in Review

14 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma (ASBP) for Q2 2023, worth a combined $17M — down 94% from $268M a quarter earlier.

Sellers outnumbered buyers: 51 funds closed out of ASBP and 8 opened new positions — a net loss of 43 holders — while 5 trimmed existing stakes and 1 added.

The largest buyer was Arena Investors, opening a new position worth an estimated $1.57M. The largest seller was Glazer Capital LLC, exiting entirely with an estimated $23.3M sold.

  • 14 institutional investors held Aspire Biopharma (ASBP) as of Q2 2023, down from 57 in Q1 2023.
  • Funds reported $17M of Aspire Biopharma stock for Q2 2023, down 94% quarter-over-quarter.
  • 8 funds opened new Aspire Biopharma positions in Q2 2023 and 51 closed out, a net change of -43 holders.
  • The largest Aspire Biopharma buyer in Q2 2023 was Arena Investors, an estimated $1.57M added.
  • The largest Aspire Biopharma seller in Q2 2023 was Glazer Capital LLC, an estimated $23.3M sold.

Based on aggregated 13F filings for Q2 2023.